Mime-Version: |
1.0 (Apple Message framework v552) |
Sender: |
|
Subject: |
|
From: |
|
Date: |
Thu, 4 Sep 2003 19:58:22 +0800 |
Content-Transfer-Encoding: |
7bit |
Content-Type: |
text/plain; charset=US-ASCII; format=flowed |
Reply-To: |
|
Parts/Attachments: |
|
|
Forwarded with permission, in case anyone else is interested.
Begin forwarded message:
> From: "Nice, Frank (NIH/NINDS)"
>
> First of all, mirtazepine is only 50% bioavailable, so of the total
> dose,
> only potentially about 50% enters the mothers systemic circulation.
> The Volume of Distribution is 107 L, which is very high, which means
> smaller
> amounts gets into the breast milk as it is distributed widely though
> out the
> body.
> It is 85% protein bound, which is very high, and means that it is more
> difficult for the drug to enter into and bid with milk protein.
> The peak concentration in plasma is 1.5 to 2 hours, so avoiding that
> time
> period while breastfeeding would mean even less of the drug would be
> available to the child.
> Based on that information, I see no need to express at all and to
> continue
> to breastfeed normally except for the peak concentration times.
[snip]
> You can see why there have been no pediatric concerns reported.
>
[snip]
--
Lara Hopkins
***********************************************
To temporarily stop your subscription: set lactnet nomail
To start it again: set lactnet mail (or digest)
To unsubscribe: unsubscribe lactnet
All commands go to [log in to unmask]
The LACTNET mailing list is powered by L-Soft's renowned
LISTSERV(R) list management software together with L-Soft's LSMTP(TM)
mailer for lightning fast mail delivery. For more information, go to:
http://www.lsoft.com/LISTSERV-powered.html
|
|
|